Offering broader access to sustainable and scalable pharma-grade saponin adjuvants
SPI Pharma, Inc. and Q-Vant Biosciences, Inc. announce a strategic partnership which includes an investment to expand Q-Vant’s proprietary 100% sustainable Q-SAP™ technology, and the signing of an exclusive commercial agreement to accelerate global adoption of their high-purity saponin adjuvants for veterinary and human vaccine formulations. WILMINGTON, Del., Oct. 13, 2023 /PRNewswire/ — SPI Pharma, […]